New drug aims to ease anemia in bone marrow cancer patients

NCT ID NCT07623161

Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 25, 2026 · Updated 7 times

Summary

This Phase 3 trial tests whether elritercept can improve anemia in people with myelofibrosis who are already taking ruxolitinib. About 324 participants will receive either elritercept or a placebo for at least 9 months. The main goal is to see if the drug reduces the need for red blood cell transfusions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: elritercept (TAK-226)
What this could lead to: If it works, this could offer a new option to reduce anemia and transfusion needs in people with myelofibrosis who are already on ruxolitinib.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The drug may not improve anemia or could cause side effects. It is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 324 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2034

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged ≥18 years at the time of signing the informed consent form (ICF). 2. Able to understand the purpose and risks of the trial and voluntarily sign an ICF. 3. Diagnosed with primary myelofibrosis (PMF), post-essential thrombocythemia (post-ET MF) or post-polycythemia vera (post-PV MF) according to the 2022 WHO criteria (WHO Classification of Tumours Editorial Board 2024), confirmed by local pathology report. 4. Transfusion status as assessed in the 12 weeks immediately preceding randomization classified as Transfusion Dependent: 3 to 8 RBC units over 12 weeks. 5. Receiving ruxolitinib (as approved in the country of the trial site) as the standard of care treatment for MF for at least 12 consecutive weeks, and on a stable daily dose for at least the 8 weeks immediately preceding the date of randomization. 6. Eastern Cooperative Oncology Group score less than or equal to (≤) 2. Exclusion Criteria: 1. Prior treatment with luspatercept, sotatercept, or other transforming growth factor beta inhibitors or activin receptor ligand traps. 2. Systemic treatment within 28 days before randomization with any of the following: 1. Androgens (including danazol). Participants on stable androgen dosing for hypogonadism for ≥8 weeks are allowed. 2. erythropoiesis-stimulating agents. 3. granulocyte colony stimulating factor or granulocyte-macrophage colony stimulating factor. 4. High dose corticosteroids. Participants on stable chronic steroid doses of prednisone ≤10 mg/day or corticosteroid equivalent for ≥4 weeks are allowed. Other treatments for autoimmune diseases may be allowed upon medical monitor review. 5. Hydroxyurea. 6. Immunomodulatory drugs (for example, thalidomide, pomalidomide, or lenalidomide). 7. Interferon. 8. Thrombopoietin receptor agonists. 9. Any investigational drug, including antihemojuvelin antibody. If the half-life of the investigational product is known, the exclusionary period prior to randomization is equal to 5 half-lives of the investigational product or 28 days, whichever is longer. 3. Initiation of new iron chelation therapy or dose adjustments to existing iron chelation therapy ≤8 weeks prior to randomization. Participants on stable doses of iron chelation therapy for ≥8 weeks are allowed. 4. Clinically significant anemia that is due to causes other than MF or Janus kinase (JAK) inhibitor therapy (for example, thalassemia, iron deficiency, vitamin B12 and/or folate deficiencies, autoimmune or hemolytic anemia, infections, or any active clinically significant bleeding or sequestration). 5. Receipt of RBC transfusion for any reason(s) other than underlying MF within 12 weeks before randomization. 6. Life expectancy \<12 months per investigator's judgment. 7. Clinically significant cardiovascular disease, defined as: 1. New York Heart Association heart disease Class III or IV; 2. Fridericia corrected QT interval \>500 millisecond (ms) during screening; 3. Uncontrolled arrhythmia, myocardial infarction, or unstable angina within 6 months before screening. 8. Uncontrolled hypertension, defined as repeated elevations of systolic blood pressure of ≥160 millimetres of mercury (mmHg) and/or diastolic blood pressure ≥100 mmHg despite adequate treatment. 9. Medical history of thromboembolic events within 6 months before screening, including history of cerebrovascular accident (including ischemic, embolic, and hemorrhagic cerebrovascular accident), transient ischemic attack, deep venous thrombosis (including proximal and distal), pulmonary or arterial embolism, arterial thrombosis, or other venous thrombosis. Participants with prior superficial thrombophlebitis are allowed. 10. Prior history of malignancies, other than MF. Participants who are free of other malignant disease for ≥2 years and have completed treatment, including maintenance, are allowed. Participants with a history or concurrent diagnosis of the following conditions are allowed if not requiring systemic therapy: 1. Basal or squamous cell carcinoma of the skin; 2. Carcinoma in situ of the cervix; 3. Carcinoma in situ of the breast; and/or 4. Incidental histologic finding of prostate cancer (T1a or T1b using the Tumour, Node, and Metastasis (TNM) staging system); 5. Early papillary thyroid cancer (stage I \[T1-T2, N0, M0\]). 11. History of solid organ or bone marrow transplantation. 12. Active infection requiring intravenous antibiotics within 28 days or oral antibiotics within 7 days before randomization. Prophylactic antibiotics and/or antifungals for neutropenia are allowed. 13. Known positivity for Human Immunodeficiency Virus (HIV), active hepatitis B virus (HBV), or active hepatitis C virus (HCV). Participants without known history of HIV, HBV, and/or HCV do not require further testing, unless testing is mandated per local guidelines. 14. Body mass index ≥40 kilograms per square meter (kg/m\^2). 15. Major surgery within 28 days before randomization. 16. History of allergy/anaphylaxis to recombinant proteins, investigational product, or excipients (refer to the current elritercept investigator's brochure for a list of excipients), or ruxolitinib. 17. Any of the following local laboratory abnormalities: 1. Absolute neutrophil count \<500/microliter (μL) (0.5×109/ liter (L)). 2. Platelet count \<50,000/μL (50×109/L) or \>1,000,000/μL (1000×109/L). 3. Blasts \>5% as assessed in peripheral blood at screening or ≥10% in any historical bone marrow assessments. Participants with isolated transient elevations of peripheral blood blasts may be eligible after discussion between the investigator and medical monitor to confirm the blast count is not indicative of disease progression. 4. Serum aspartate aminotransferase or alanine aminotransferase ≥3× the upper limit of normal (ULN). 5. Total bilirubin ≥2×ULN. Participants with known history of Gilbert syndrome with unconjugated bilirubin less than (\<) 3×ULN are allowed. Higher levels if attributed to active RBC precursor destruction within the bone marrow (ineffective erythropoiesis) may be allowed upon medical monitor review. 6. Estimated glomerular filtration rate \<30 milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2) as determined by the Chronic Kidney Disease Epidemiology Collaboration equation. 7. Ferritin ≤50 micrograms per liter (μg/L). 8. Folate ≤2.0 nanograms per milliliter (ng/mL). 9. Vitamin B12 ≤200 picograms per milliliter (pg/mL). 18. Ongoing participation in another interventional clinical trial. 19. Participant is unwilling or, in the opinion of the investigator, the participant is unable to comply with the requirements of the protocol. 20. Is a person of childbearing potential but does not agree to use at least 1 form of highly effective contraception from the time of signing the ICF until at least 60 days after the last dose of elritercept or placebo. 21. Participants of male birth who are fertile and who have partners of childbearing potential, who do not agree to use acceptable barrier contraception, that is, a male condom, during the entire treatment period until at least 60 days after the last dose of elritercept or placebo. 22. If applicable, participant with a positive serum pregnancy test during the screening period or known to be pregnant or a lactating participant who does not agree to forego breastfeeding during the entire treatment period until at least 60 days after the last dose of elritercept or placebo. 23. For participants in France: Persons under court protection, persons not affiliated with a social security system, and protected adults.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anemia Myelofibrosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

The study's own enquiry address

This study publishes an address for enquiries. See it below .
The places running it

195 sites in 31 countries. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

AOU Citta della Salute e della Scienza di Torino
NOT_YET_RECRUITING

Torino, 10126, Italy
AZ Delta
NOT_YET_RECRUITING

Roeselare, West-Vlaanderen, 8800, Belgium
Advanced Research, LLC
RECRUITING

Coral Springs, Florida, 33065, United States
AdventHealth - Cancer Institute - Orlando
NOT_YET_RECRUITING

Orlando, Florida, 32804-4648, United States
Alexandra General Hospital of Athens
NOT_YET_RECRUITING

Athens, Attica, 11528, Greece
All India Institute of Medical Science
NOT_YET_RECRUITING

New Delhi, National Capital Territory of Delhi, 110029, India
Allegheny Health Network Cancer Institute - West Penn Hospital Location
NOT_YET_RECRUITING

Pittsburgh, Pennsylvania, 15224, United States
Amrita Institute of Medical Sciences
NOT_YET_RECRUITING

Kochi, Kerala, 682041, India
Ankara Bilkent City Hospital
NOT_YET_RECRUITING

Çankaya, Ankara, 06800, Turkey (Türkiye)
Apollo Hospital Hyderabad
NOT_YET_RECRUITING

Hyderabad, Telangana, 500096, India
Apollo Specialty Hospitals
NOT_YET_RECRUITING

Chennai, Tamil Nadu, 382424, India
Assistance Publique Hopitaux de Paris
NOT_YET_RECRUITING

Paris, Paris, 75015, France
Azienda Ospedaliera Universitaria Careggi
NOT_YET_RECRUITING

Florence, 50134, Italy
Azienda Ospedaliero-Universitaria delle Marche; SOD Clinica Medica
NOT_YET_RECRUITING

Ancona, 60121, Italy
Azienda Sanitaria Universitaria Friuli Centrale
NOT_YET_RECRUITING

Udine, 33100, Italy
BRCR Global
NOT_YET_RECRUITING

Córdoba, 5000, Argentina
Banner MD Anderson Cancer Center
NOT_YET_RECRUITING

Gilbert, Arizona, 85234, United States
Baylor University Medical Center
NOT_YET_RECRUITING

Dallas, Texas, 75246, United States
Bioresearch Partners
NOT_YET_RECRUITING

Miami, Florida, 33143, United States
Birmingham Heartlands Hospital
NOT_YET_RECRUITING

Birmingham, W Mids, United Kingdom
CHU Namur Site Mont Godinne
NOT_YET_RECRUITING

Yvoir, 5530, Belgium
CHU de Bordeaux
NOT_YET_RECRUITING

Pessac, Gironde, 33600, France
CHU de Nice
NOT_YET_RECRUITING

Nice, Alpes Maritimes, 6002, France
CHU de Poitiers
NOT_YET_RECRUITING

Poitiers, Vienne, 86021, France
CHU de Strasbourg
NOT_YET_RECRUITING

Strasbourg, Bas Rhin, 67200, France
Cancer and Blood Specialty Clinic
NOT_YET_RECRUITING

Whittier, California, 90603, United States
Carmel Medical Center
NOT_YET_RECRUITING

Haifa, 3436212, Israel
Centre Hospitalier Jolimont-Lobbes
NOT_YET_RECRUITING

La Louvière, Hainaut, 7100, Belgium
Centre Hospitalier Lyon Sud
NOT_YET_RECRUITING

Pierre-Bénite, Auvergne-Rhône-Alpes, 69495, France
Centre Hospitalier Regional Universitaire Brest Hopital Morvan
NOT_YET_RECRUITING

Brest, Finistere, 29609, France
Centre Hospitalier Regional Universitaire de Lille
NOT_YET_RECRUITING

Lille, Nord, 59037, France
Centro de Ensino, Pesquisa e Inovacao do Hospital Sao Lucas (CEPIN HSL RJ / Rede Americas)
NOT_YET_RECRUITING

Rio de Janeiro, Rio de Janeiro, 22061080, Brazil
Centro de Hematologia e Oncologia (CHO)
NOT_YET_RECRUITING

Joinville, Santa Catarina, 89201-260, Brazil
Centro de Oncologia de Precision
NOT_YET_RECRUITING

Santiago, Santiago Metropolitan, 7850000, Chile
Chiba Cancer Center
NOT_YET_RECRUITING

Chiba, Chiba, 260-8717, Japan
Cleveland Clinic
NOT_YET_RECRUITING

Cleveland, Ohio, 44195, United States
Clinica General del Norte De Barranquilla
NOT_YET_RECRUITING

Barranquilla, Atlántico, 080002, Colombia
Colentina Clinical Hospital
NOT_YET_RECRUITING

Bucharest, 20125, Romania
Cork University Hospital
NOT_YET_RECRUITING

Cork, T12 DC4A, Ireland
Daegu Catholic University Medical Center
NOT_YET_RECRUITING

Daegu, 42472, South Korea
Debreceni Egyetem Klinikai Kozpont Belgyogyaszati Klinika
NOT_YET_RECRUITING

Debrecen, HB, 4032, Hungary
Dr. Pencho Georgiev - Outpatient Center
NOT_YET_RECRUITING

Plovdiv, 4002, Bulgaria
Duke Blood Cancer Center
NOT_YET_RECRUITING

Durham, North Carolina, 27705, United States
Ehime University Hospital
NOT_YET_RECRUITING

Toon-shi, Ehime, 791-0295, Japan
Emory University
NOT_YET_RECRUITING

Atlanta, Georgia, 30322, United States
Fakultni nemocnice Hradec Kralove
NOT_YET_RECRUITING

Hradec Králové, CZ, 50005, Czechia
Fakultni nemocnice Kralovske Vinohrady
NOT_YET_RECRUITING

Prague, 134 00, Czechia
Flinders Medical Centre
NOT_YET_RECRUITING

Bedford Park, Adelaide, SA, 5042, Australia
Florida Clinical Trials Group
NOT_YET_RECRUITING

Tamarac, Florida, 33321, United States
Fondazione Irccs Ca' Granda Ospedale Maggioe Policlinico Di Milano
NOT_YET_RECRUITING

Milan, MI, 20122, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NOT_YET_RECRUITING

Rome, RM, 00168, Italy
Funcacion santa Fe De Bogota
NOT_YET_RECRUITING

Bogota, Cundinamarca, 11011, Colombia
General Hospital
NOT_YET_RECRUITING

Athens, Attica, 11527, Greece
Grupo Elora Pesquisa Clinica
NOT_YET_RECRUITING

Florianópolis, Santa Catarina, 88020-210, Brazil
Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
NOT_YET_RECRUITING

London, SE1 9RT, United Kingdom
Hadassah Medical Organization, Hadassah Medical Center, Ein-
NOT_YET_RECRUITING

Jerusalem, 9112001, Israel
Hematologica Alta Especialidad S.C.
NOT_YET_RECRUITING

Huixquilucan, Mexico de Mexico, 52787, Mexico
Hitachi General Hospital
NOT_YET_RECRUITING

Hitachi, Ibaraki, 317-0077, Japan
Hospital Aleman (HA) Deutsches Hospital
NOT_YET_RECRUITING

Buenos Aires, CPC1118AAT, Argentina
Hospital Amaral Carvalho (HAC)
NOT_YET_RECRUITING

Jaú, São Paulo, 17210-080, Brazil
Hospital Ampang
NOT_YET_RECRUITING

Ampang, Selangor, 68000, Malaysia
Hospital Cliniico Regional de Concepcion Dr
NOT_YET_RECRUITING

Concepción, Biobio, 4030000, Chile
Hospital Mae De Deus - Integrated Oncology Center
NOT_YET_RECRUITING

Porto Alegre, Rio Grande do Sul, 90110-270, Brazil
Hospital Pablo Tobon Uribe
NOT_YET_RECRUITING

Medellín, Antioquia, 0000000, Colombia
Hospital Privado de Rosario
NOT_YET_RECRUITING

Rosario, Santa Fe Province, S2000GAP, Argentina
Hospital Pulau Pinang
NOT_YET_RECRUITING

George Town, Pulau Pinang, 10990, Malaysia
Hospital Queen Elizabeth
NOT_YET_RECRUITING

Kota Kinabalu, Sabah, 88586, Malaysia
Hospital Ramon Y Cajal
NOT_YET_RECRUITING

Madrid, 28034, Spain
Hospital Sao Lucas da PUCRS
NOT_YET_RECRUITING

Porto Alegre, Rio Grande do Sul, 90610-000, Brazil
Hospital Universitari Vall d'Hebron
NOT_YET_RECRUITING

Barcelona, 08035, Spain
Hospital Universitari i Politecnic La Fe
NOT_YET_RECRUITING

Valencia, 46026, Spain
Hospital Universitario Austral
NOT_YET_RECRUITING

Pilar, Buenos Aires, B1629AHJ, Argentina
Hospital Universitario Virgen de la Victoria
NOT_YET_RECRUITING

Málaga, M, 29003, Spain
Hospital Universitario de Gran Canaria Doctor Negrin
NOT_YET_RECRUITING

Las Palmas de Gran Canaria, LAS Palmas, 35010, Spain
IC La Serena Research
NOT_YET_RECRUITING

La Serena, Coquimbo Region, 01697, Chile
IRCCS - AOU di Bologna - Sant Orsola Malpighi
NOT_YET_RECRUITING

Bologna, BO, 40138, Italy
Icahn School of Medicine at Mount Sinai
NOT_YET_RECRUITING

New York, New York, 10029, United States
Icegclinic
NOT_YET_RECRUITING

Santiago, La Florida, 8241479, Chile
Immunocel
NOT_YET_RECRUITING

Las Condes, Santiago Metropolitan, 7560908, Chile
Imperial College Healthcare NHS Trust
NOT_YET_RECRUITING

London, London, City of, W12 0HS, United Kingdom
Institut Catala d'Oncologia
NOT_YET_RECRUITING

Badalona, Barcelona, 8916, Spain
Institut Catala d'Oncologia Hospital Duran y Renals
NOT_YET_RECRUITING

L'Hospitalet de Llobregat, Barcelona, 08908, Spain
Institut Paoli Calmettes
NOT_YET_RECRUITING

Marseille, Bouches-du-Rhone, 13009, France
Institut fur Versorgungsforschung in der Onkologie GbR
NOT_YET_RECRUITING

Koblenz, Rhineland-Palatinate, 56068, Germany
Instituto Medico de la Fundacion Estudios Clinicos
NOT_YET_RECRUITING

Rosario, Santa Fe Province, 2000, Argentina
Institutul Oncologic Prof. Dr. Ion Chiricuta
NOT_YET_RECRUITING

Cluj-Napoca, CJ, 400124, Romania
Ippokrateion Hospital of Thessaloniki
NOT_YET_RECRUITING

Thessaloniki, Macedonia, 54642, Greece
Istanbul Florence Nightingale Hospital
NOT_YET_RECRUITING

Istanbul, 34381, Turkey (Türkiye)
Istanbul University-CerrahpaAYa, CerrahpaAYa Faculty of Medicine
NOT_YET_RECRUITING

Istanbul, 34303, Turkey (Türkiye)
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l
NOT_YET_RECRUITING

Meldola, Forli-Cesena, 47014, Italy
Jewish General Hospital
NOT_YET_RECRUITING

Montreal, Quebec, H3T1E2, Canada
Juravinski Cancer Centre
NOT_YET_RECRUITING

Hamilton, Ontario, L8V 5C2, Canada
Kaohsiung Medical University Hospital
NOT_YET_RECRUITING

Kaohsiung City, Taiwan
Karolinska University Hospital
NOT_YET_RECRUITING

Stockholm, 14186, Sweden
King Faisal Specialist Hospital & Research Centre Riyadh
NOT_YET_RECRUITING

Riyadh, 11211, Saudi Arabia
King Khalid University Hospital
NOT_YET_RECRUITING

Riyadh, 12372, Saudi Arabia
Kliniken Ostalb
NOT_YET_RECRUITING

Mutlangen, Baden-Wurttemberg, 73557, Germany
Klinikum Chemnitz GmbH
NOT_YET_RECRUITING

Chemnitz, Saxony, 9116, Germany
Klinikum Wels-Grieskirchen
NOT_YET_RECRUITING

Wels, Upper Austria, 4600, Austria
Kobe City Medical Center General Hospital
NOT_YET_RECRUITING

Kobe, Hyōgo, 650-0047, Japan
Komarom-Esztergom Varmegyei Szent Borbala Korhaz
NOT_YET_RECRUITING

Tatabánya, Komarom-Esztergom VArmegye, 2800, Hungary
Korea University Anam Hospital
NOT_YET_RECRUITING

Seoul, Seongbuk-gu, South Korea
LUMI Research
RECRUITING

Houston, Texas, 77090, United States
Laiko General Hospital of Athens
NOT_YET_RECRUITING

Athens, Attica, 11526, Greece
Los Angeles Cancer Network
NOT_YET_RECRUITING

Glendale, California, 91204, United States
Los Cobos Medical Center
NOT_YET_RECRUITING

Bogotá, Bogota D.C., 110121, Colombia
MD Anderson Cancer Center
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
MTZ Clinical Research Powered by PRATIA
NOT_YET_RECRUITING

Warsaw, Masovian Voivodeship, 02-172, Poland
Masaryk University Hospital Brno, Department of Internal Medicine, Hematology and Oncology
NOT_YET_RECRUITING

Brno, Czech Republic, 625 00, Czechia
Mater Misericordiae University Hospital
NOT_YET_RECRUITING

Dublin, D15 W8Y7, Ireland
Max Super Specialty Hospital
NOT_YET_RECRUITING

Delhi, 201012, India
McGill University Health Center
NOT_YET_RECRUITING

Montreal, Quebec, H4A 3J1, Canada
MedStar Georgetown University Hospital
NOT_YET_RECRUITING

Washington D.C., District of Columbia, 20007, United States
Medanta- The Medicity- Gurugram
NOT_YET_RECRUITING

Gurgaon, Haryana, 122001, India
Medical University of South Carolina
NOT_YET_RECRUITING

Charleston, South Carolina, 29425, United States
Medizinische Universitat Innsbruck
NOT_YET_RECRUITING

Innsbruck, Tyrol, 6020, Austria
Medizinische Universitat Wien (Medical University of Vienna - Austria)
NOT_YET_RECRUITING

Vienna, A, 1090, Austria
Memorial Sloan Kettering Cancer Center
NOT_YET_RECRUITING

New York, New York, 10021, United States
Mid North Coast Cancer Institute (MNCCI)
NOT_YET_RECRUITING

Coffs Harbour, New South Wales, 2450, Australia
Mie University Hospital
NOT_YET_RECRUITING

Tsu, Mie-ken, 514-8507, Japan
Moffit Cancer Center
NOT_YET_RECRUITING

Tampa, Florida, 33612, United States
Muehlenkreiskliniken AoeR-Johannes Wesling Klinikum Minden - Universitaetsklinik fuer Neurologie und Neurogeriatrie
NOT_YET_RECRUITING

Minden, North Rhine-Westphalia, 32429, Germany
National Cheng Kung University Hospital
NOT_YET_RECRUITING

Tainan, 70403, Taiwan
National Taiwan University Hospital
NOT_YET_RECRUITING

Taipei, Taiwan (r.o.c.), 100, Taiwan
Novant Health
NOT_YET_RECRUITING

Winston-Salem, North Carolina, 27103, United States
OSMO - Oaxaca Site Management Organization S.C
NOT_YET_RECRUITING

Oaxaca City, Oaxaca, 68000, Mexico
Olympion General Clinic & Rehabilitation Center
NOT_YET_RECRUITING

Pátrai, Ahaia, 264 43, Greece
Ordensklinikum Linz Elisabethinen
NOT_YET_RECRUITING

Linz, 4020, Austria
Orebro University Hospital
NOT_YET_RECRUITING

Örebro, 70185, Sweden
Oregon Health and Science University
NOT_YET_RECRUITING

Portland, Oregon, 97239, United States
Ospedale S Eugenio
NOT_YET_RECRUITING

Rome, Lazio, 144, Italy
Policlinico Universitario di Catania
NOT_YET_RECRUITING

Catania, 95124, Italy
Porto Alegre Clinical Hospital (HCPA)
NOT_YET_RECRUITING

Porto Alegre, Rio Grande do Sul, 90035-903, Brazil
Portuguese Charity of Sao Paulo
NOT_YET_RECRUITING

São Paulo, 01323-900, Brazil
Pratia Oncology Katowice
NOT_YET_RECRUITING

Katowice, Silesian Voivodeship, 40-519, Poland
Pratia Poznan
NOT_YET_RECRUITING

Poznan, Greater Poland Voivodeship, 60-192, Poland
Praxis am Volkspark
NOT_YET_RECRUITING

Berlin, 10715, Germany
Princess Margaret Cancer Centre
NOT_YET_RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Rabin Medical Center
NOT_YET_RECRUITING

Petah Tikva, 4941492, Israel
Rajiv Gandhi Cancer Institute and Research Centre
NOT_YET_RECRUITING

Rohini, NEW Delhi, 110085, India
Rambam Health Care Campus
NOT_YET_RECRUITING

Haifa, North, 3109601, Israel
Regional cancer Centre
NOT_YET_RECRUITING

Thiruvananthapuram, Kerala, 695011, India
Sahyadri Super Speciality Hospital Deccan
NOT_YET_RECRUITING

Pune, Maharashtra, 411004, India
Samsung Medical Center
NOT_YET_RECRUITING

Seoul, Gangnam-gu, South Korea
Seoul National University Bundang Hospital
NOT_YET_RECRUITING

Seongnam-si, Gyeonggi-do, 13620, South Korea
Seoul National University Hospital
NOT_YET_RECRUITING

Seoul, 3080, South Korea
Soon Chun Hyang University Hospital Seoul
NOT_YET_RECRUITING

Seoul, Seoul Teugbyeolsi, 04401, South Korea
South Eastern Sydney Local Health District
NOT_YET_RECRUITING

Kogarah, New South Wales, 2217, Australia
Specialized Hospital for Active Treatment of Haematological Diseases - Sofia
NOT_YET_RECRUITING

Sofia, 1797, Bulgaria
Spitalul Clinic Municipal de Urgenta Timisoara
NOT_YET_RECRUITING

Timișoara, 300700, Romania
Spitalul Municipal Filantropia Craiova
NOT_YET_RECRUITING

Craiova, Dolj, 200143, Romania
St James's Hospital
NOT_YET_RECRUITING

Dublin, D08 NHY1, Ireland
St. Vincent Regional Hospital Cancer Centers
NOT_YET_RECRUITING

Billings, Montana, 59101, United States
Sunderland and South Tyneside NHS Foundation Trust
NOT_YET_RECRUITING

Sunderland, Tyne and Wear, SR4 7TP, United Kingdom
Swiss Medical Center Barrio Parque
NOT_YET_RECRUITING

Buenos Aires, Ciudad Autonoma de BuenosAires, 1405, Argentina
Taichung Veterans General Hospital
NOT_YET_RECRUITING

Taichung, 40705, Taiwan
Taipei Veterans General Hospital
NOT_YET_RECRUITING

Taipei, Beitou, 11217, Taiwan
Tata Medical Center, Kolkata
NOT_YET_RECRUITING

Kolkata, West Bengal, 700 160, India
The Catholic University of Korea
NOT_YET_RECRUITING

Seoul, 137-701, South Korea
The Tel Aviv Sourasky Medical Center
NOT_YET_RECRUITING

Tel Aviv, TLV, 64239, Israel
The University of Utah-Huntsman Cancer Institute
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
Thomas Jefferson University
NOT_YET_RECRUITING

Philadelphia, Pennsylvania, 19107, United States
Tokyo Metropolitan Komagome Hospital
NOT_YET_RECRUITING

Bunkyo-Ku, Tokyo, 113-8677, Japan
Tufts Medical Center
NOT_YET_RECRUITING

Boston, Massachusetts, 02111, United States
Tweed Valley Hospital
NOT_YET_RECRUITING

Cudgen, New South Wales, 2487, Australia
UCL Cancer Institute - University College London Hospitals NHS Foundation Trust
NOT_YET_RECRUITING

London, NW1 2PG, United Kingdom
UMHAT 'Dr. Georgi Stranski', EAD
NOT_YET_RECRUITING

Pleven, 5800, Bulgaria
UMHAT Sv. Ivan Rilski
NOT_YET_RECRUITING

Sofia, 1431, Bulgaria
UZ Leuven
NOT_YET_RECRUITING

Leuven, Vlaams-Brabant, 3000, Belgium
United Lincolnshire Teaching Hospitals NHS Trust
NOT_YET_RECRUITING

Lincoln, East Midlands, LN2 5QY, United Kingdom
Universidad Autonoma de Nuevo Leon
NOT_YET_RECRUITING

Monterrey, Mexic, 64710, Mexico
Universidad de Salamanca - Hospital Universitario de Salamanca
NOT_YET_RECRUITING

Salamanca, 37007, Spain
Universita degli Studi di Roma La Sapienza - Umberto I Policlinico di Roma
NOT_YET_RECRUITING

Rome, Lazio, 00161, Italy
Universitaetsklinikum Freiburg
NOT_YET_RECRUITING

Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
Universitaetsklinikum Heidelberg (UKHD)
NOT_YET_RECRUITING

Heidelberg, Baden-Wurttemberg, 69120, Germany
Universitaetsklinikum Jena
NOT_YET_RECRUITING

Jena, Thuringia, 7743, Germany
Universitaria di Ferrara Azienda Ospedaliero
NOT_YET_RECRUITING

Cona, Ferrara, 44124, Italy
University Hospital Galway
NOT_YET_RECRUITING

Galway, H91YR71, Ireland
University Hospital Halle (Saale)
NOT_YET_RECRUITING

Halle, Saxony-Anhalt, 06120, Germany
University Hospital of Leicester NHS
NOT_YET_RECRUITING

Leicester, Leicestershire, LE1 5WW, United Kingdom
University Malaya Medical Centre
NOT_YET_RECRUITING

Kuala Lumpur, Kuala Lumpur, 59100, Malaysia
University of Crete
NOT_YET_RECRUITING

Heraklion, Crete, 70013, Greece
University of Miyazaki Hospital
NOT_YET_RECRUITING

Miyazaki, Miyazaki, 889-1692, Japan
University of New Mexico Comprehensive Cancer Center
NOT_YET_RECRUITING

Albuquerque, New Mexico, 87102, United States
University of Pittsburgh Medical Center
NOT_YET_RECRUITING

Pittsburgh, Pennsylvania, 15219, United States
University of Washington
NOT_YET_RECRUITING

Seattle, Washington, 98109, United States
University of Yamanashi Hospital
NOT_YET_RECRUITING

Chuo-shi, Yamanashi, 409-3898, Japan
VM Medical Park Mersin Hospital
NOT_YET_RECRUITING

Mersin, Mezitli, 33000, Turkey (Türkiye)
Vanderbilt-Ingram Cancer Center (VICC)-Nashville
NOT_YET_RECRUITING

Nashville, Tennessee, 37232-0021, United States
Vseobecna fakultni nemocnice Praha
NOT_YET_RECRUITING

Prague, CZ, 12808, Czechia
Washington University School of Medicine
NOT_YET_RECRUITING

St Louis, Missouri, 63110, United States
Wojewodzki Szpital Zespolony Im L Rydygiera
NOT_YET_RECRUITING

Torun, Kuyavian-Pomeranian Voivodeship, 87-100, Poland
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Oddzial Hematologii
NOT_YET_RECRUITING

Lodz, Łódź Voivodeship, 93-513, Poland
Zespol Szpitali Miejskich w Chorzowie
NOT_YET_RECRUITING

Chorzów, Silesian Voivodeship, 41-500, Poland
Ziekenhuis aan de Stroom-Cadix
NOT_YET_RECRUITING

Antwerp, 2030, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.